Literature DB >> 1459729

Establishment of a murine model of malignant mesothelioma.

M R Davis1, L S Manning, D Whitaker, M J Garlepp, B W Robinson.   

Abstract

Malignant mesothelioma (MM) is an aggressive tumour of the serosal cavities which is associated with previous asbestos exposure and is generally found to be resistant to conventional forms of therapy. Adequate scientific and clinical assessment of this disease has been severely limited by the relatively low incidence of mesothelioma and the lack of representative cell lines and animal models. The purpose of this study was to develop an asbestos-induced murine model of MM both as an in vivo-passaged malignancy and as in vitro-established cell lines. Such a model system would be invaluable for use in the study of various cellular, molecular and genetic aspects of the disease, and for the pre-clinical evaluation of potential therapeutic agents. BALB/c and CBA mice were injected intraperitoneally with crocidolite asbestos. Seven to 25 months after exposure, 35% of the mice developed mesothelioma (5 BALB/c, 9 CBA), as determined by standard cytological and histological parameters. From these primary tumours, 12 continuously growing cell lines (5 BALB/c, 7 CBA) were established in culture. All have been confirmed as mesothelioma by cytological and ultrastructural (electron microscopy) analyses. These lines have been in culture for 7 to 24 months and have achieved passages above 32 (range 32 to 106). As in the human disease, the murine mesothelioma lines vary in their morphology and growth rates (doubling times ranging from 14 to 30 hr). All cell lines produced tumours when injected into syngeneic mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459729     DOI: 10.1002/ijc.2910520609

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  60 in total

Review 1.  The Role of Regulatory T Cells in Mesothelioma.

Authors:  Demelza J Ireland; Haydn T Kissick; Manfred W Beilharz
Journal:  Cancer Microenviron       Date:  2012-02-01

2.  Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.

Authors:  Pascal Andujar; Céline Lecomte; Annie Renier; Jocelyne Fleury-Feith; Laurence Kheuang; Julien Daubriac; Anne Janin; Marie-Claude Jaurand
Journal:  Carcinogenesis       Date:  2007-02-01       Impact factor: 4.944

3.  Intraoperative near-infrared imaging of surgical wounds after tumor resections can detect residual disease.

Authors:  Brian Madajewski; Brendan F Judy; Anas Mouchli; Veena Kapoor; David Holt; May D Wang; Shuming Nie; Sunil Singhal
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

4.  Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.

Authors:  Jingying Zhou; Allen Kl Cheung; Henggui Liu; Zhiwu Tan; Xian Tang; Yuanxi Kang; Yanhua Du; Haibo Wang; Li Liu; Zhiwei Chen
Journal:  Mol Ther       Date:  2013-04-16       Impact factor: 11.454

5.  Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

Authors:  Samuel Kim; George Buchlis; Zvi G Fridlender; Jing Sun; Veena Kapoor; Guanjun Cheng; Andrew Haas; Hung Kam Cheung; Xiamei Zhang; Michael Corbley; Larry R Kaiser; Leona Ling; Steven M Albelda
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Authors:  Candice L Willmon; Vassiliki Saloura; Zvi G Fridlender; Phonphimon Wongthida; Rosa Maria Diaz; Jill Thompson; Timothy Kottke; Mark Federspiel; Glen Barber; Steven M Albelda; Richard G Vile
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

7.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

8.  Combination immune checkpoint blockade as an effective therapy for mesothelioma.

Authors:  Vanessa S Fear; Caitlin Tilsed; Jonathan Chee; Catherine A Forbes; Thomas Casey; Jessica N Solin; Sally M Lansley; William Joost Lesterhuis; Ian M Dick; Anna K Nowak; Bruce W Robinson; Richard A Lake; Scott A Fisher
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

9.  Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.

Authors:  Joris D Veltman; Margaretha E H Lambers; Menno van Nimwegen; Sanne de Jong; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts; Joost P J J Hegmans
Journal:  J Biomed Biotechnol       Date:  2010-05-23

10.  Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.

Authors:  A-S Bergot; A Durgeau; B Levacher; B M Colombo; J L Cohen; D Klatzmann
Journal:  Cancer Gene Ther       Date:  2010-05-14       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.